Th17 cells in cancer

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Volumn , Issue , 2014, Pages 37-75

  Paulos, Chrystal M ^a   Nelson, Michelle H ^a   Yu, Xue Zhong ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cancer; IL 17A; Immunology; Immunotherapy; Plasticity; ROR t; Th17; Transplantation; Tumor microenvironment

Indexed keywords

EID: 84929674912     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4899-8056-4_2     Document Type: Chapter

References (176)

1. Muranski P, Restifo NP (2009) Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 21(2):200-208
2. Zou W, Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10(4):248-256. doi:10.1038/nri2742
3. Martin F, Apetoh L, Ghiringhelli F (2012) Controversies on the role of Th17 in cancer: a TGF-beta-dependent immunosuppressive activity? Trends Mol Med 18(12):742-749. doi:S1471-4914(12)00184-0 [pii]10.1016/j.molmed.2012.09.007
4. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136(7):2348-2357
5. Kidd P (2003) Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8(3):223-246
6. Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112(5):1557-1569. doi:112/5/1557 [pii]10.1182/blood-2008-05-078154
7. Steinman L (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13(2):139-145. doi:nm1551 [pii]10.1038/nm1551
8. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485-517. doi:10.1146/annurev.immunol.021908.13271010.1146/annurev.immunol.021908.132710 [pii]
9. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123-1132. doi:ni1254 [pii]10.1038/ni1254
10. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6(11):1133-1141. doi:ni1261 [pii]10.1038/ni1261
11. Zhu J, Yamane H, Paul WE (2010) Differentiation of effector CD4 T cell populations (∗). Annu Rev Immunol 28:445-489. doi:10.1146/annurev-immunol-030409-101212
12. Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531-564. doi:10.1146/annurev. immunol.25.022106.141623
13. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100(6):655-669. doi:S0092-8674(00)80702-3 [pii]
14. Zheng W, Flavell RA (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89(4):587-596. doi:S0092-8674 (00)80240-8 [pii]
15. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN (2004) Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200(6):771-782. doi:10.1084/jem.20041130jem.20041130 [pii]
16. Antony PA, Restifo NP (2005) CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28(2):120-128. doi:00002371-200503000-00002 [pii]
17. Hirahara K, Ghoreschi K, Laurence A, Yang XP, Kanno Y, O'Shea JJ (2010) Signal transduc-tion pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev 21(6):425-434. doi:S1359-6101(10)00073-0 [pii]10.1016/j.cytogfr.2010.10.006
18. Ivanov, II, Zhou L, Littman DR (2007) Transcriptional regulation of Th17 cell differentiation. Semin Immunol 19(6):409-417. doi:S1044-5323(07)00088-7 [pii]10.1016/j. smim.2007.10.011
19. Stritesky GL, Yeh N, Kaplan MH (2008) IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 181(9):5948-5955. doi:181/9/5948 [pii]
20. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA (2006) Interleukin (IL)-22 and IL-17 are coexpressedbyTh17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203(10):2271-2279. doi:jem.20061308 [pii]10.1084/jem.20061308
21. Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8(5):337-348. doi:nri2295 [pii]10.1038/nri2295
22. Chang SH, Dong C (2007) A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 17(5):435-440. doi:cr200735 [pii]10.1038/cr.2007.35
23. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+Thelper cells. Cell 126(6):1121-1133. doi:S0092-8674(06)01105-6 [pii]10.1016/j.cell.2006.07.035
24. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206(1):43-49. doi:jem.20081438 [pii]10.1084/jem.20081438
25. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453 (7191) :106-109. doi:nature06881 [pii]10.1038/nature06881
26. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, Agarwal A, Huang W, Parkurst CN, Muratet M, Newberry KM, Meadows S, Greenfield A, Yang Y, Jain P, Kirigin FK, Birchmeier C, Wagner EF, Murphy KM, Myers RM, Bonneau R, Littman DR (2012) A validated regulatory network for Th17 cell specification. Cell 151(2):289-303. doi:S0092-8674(12)01123-3 [pii]10.1016/j.cell.2012.09.016
27. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G (2007) Surface phenotype and antigenic specificity of human in-terleukin 17-producing T helper memory cells. Nat Immunol 8(6):639-646. doi:ni1467 [pii]10.1038/ni1467
28. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH (2010) The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med 2(55):55ra78. doi:2/55/55ra78 [pii]10.1126/scitranslmed.3000448
29. Morishima N, Mizoguchi I, Takeda K, Mizuguchi J, Yoshimoto T (2009) TGF-betaisnecessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem Biophys Res Commun 386(1):105-110. doi:S0006-291X(09)01115-2 [pii]10.1016/j.bbrc.2009.05.140
30. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, Rodolico G, Querci V, Ab-bate G, Angeli R, Berrino L, Fambrini M, Caproni M, Tonelli F, Lazzeri E, Parronchi P, Liotta F, Maggi E, Romagnani S, Annunziato F (2008) Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med 205(8):1903-1916. doi:jem.20080397 [pii]10.1084/jem.20080397
31. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R (2012) Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 188(11):5438-5447. doi:jimmunol.1103801 [pii]10.4049/jimmunol.1103801
32. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, Lang S, Jackson EK, Gorelik E, Whiteside TL (2010) Generation and accumulation of immunosup-pressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem 285(10):7176-7186. doi:M109.047423 [pii]10.1074/jbc.M109.047423
33. Reinhold D, Bank U, Tager M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S (2008) DP IV/CD26, APN/CD13 and related enzymes asregulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis. Front Biosci 13:2356-2363. doi:2849 [pii]
34. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, FazekasdeStGroth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203(7):1701-1711. doi:jem.20060772 [pii]10.1084/jem.20060772
35. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A (2010) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130(5):1373-1383. doi:jid2009399 [pii]10.1038/jid.2009.399
36. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2011) Increasing levelsofcirculat-ing Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther 13(4):R126. doi:ar3431 [pii]10.1186/ar3431
37. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP, Zheng L (2009) Increasedintratu-moral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50(5):980-989. doi:S0168-8278(09)00086-5 [pii]10.1016/j.jhep.2008.12.033
38. Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B (2010) Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 103(8):1245-1254. doi:6605891 [pii]10.1038/sj.bjc.6605891
39. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, Izawa S, Fujii H (2010) Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 101(9):1947-1954. doi:CAS1624 [pii]10.1111/j.1349-7006.2010.01624.x
40. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71(4):1263-1271. doi:0008-5472.CAN-10-2907 [pii]10.1158/0008-5472.CAN-10-2907
41. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184(3):1630-1641. doi:jimmunol.0902813 [pii]10.4049/jimmunol.0902813
42. Albert ML, Birthe S, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (6671) :86-89
43. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114(6):1141-1149. doi:blood-2009-03-208249 [pii]10.1182/blood-2009-03-208249
44. Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, Pawelec G (2009) Pretreatment frequency of circulating IL-17+CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 125(6):1372-1379. doi:10.1002/ijc.24497
45. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, Zhu B, Chen Z (2010) Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 69(3):348-354. doi:S0169-5002(09)00590-X [pii]10.1016/j.lungcan.2009.11.013
46. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM (2009) Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 69(13):5522-5530. doi:0008-5472.CAN-09-0266 [pii]10.1158/0008-5472.CAN-09-0266
47. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, Stebbing J (2009) The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer 100(7):1061-1067. doi:6604963 [pii]10.1038/sj.bjc.6604963
48. Wang W, Edington HD, Rao UN, Jukic DM, Radfar A, Wang H, Kirkwood JM (2008) Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 14(24):8314-8320. doi:14/24/8314 [pii]10.1158/1078-0432.CCR-08-0705
49. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35. doi:1479-5876-7-35 [pii]10.1186/1479-5876-7-35
50. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, Jagannath S, Dhodapkar MV (2008) Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112(7):2878-2885. doi:blood-2008-03-143222 [pii]10.1182/blood-2008-03-143222
51. Zhou P, Sha H, Zhu J (2010) The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res 38(2):611-619
52. Li P, Ji M, Park J, Bunting KD, Ji C, Tse W (2012) Th17 related cytokines in acute myeloid leukemia. Front Biosci 17:2284-2294. doi:4052 [pii]
53. Sawada Y, Nakamura M, Kabashima-Kubo R, Shimauchi T, Kobayashi M, Tokura Y (2012) Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia/lymphoma. Clin Cancer Res 18(14):3772-3779. doi:1078-0432.CCR-12-0292 [pii]10.1158/1078-0432.CCR-12-0292
54. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L (2010) Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 51(1):154-164. doi:10.1002/hep.23291
55. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B (2012) Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 97(4):599-607. doi:haematol.2011.047316 [pii]10.3324/haematol.2011.047316
56. Qian X, Gu L, Ning H, Zhang Y, Hsueh EC, Fu M, Hu X, Wei L, Hoft DF, Liu J (2013) Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2. J Immunol 190(11):5894-5902. doi:10.4049/jimmunol.1203141
57. Obermajer N, Wong JL, Edwards RP, Chen K, Scott M, Khader S, Kolls JK, Odunsi K, Billiar TR, Kalinski P (2013) Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling. J Exp Med. doi:10.1084/jem.20121277
58. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114(2):357-359. doi:blood-2008-09-177360 [pii]10.1182/blood-2008-09-177360
59. Shen H, Clauss M, Ryan J, Schmidt AM, Tijburg P, Borden L, Connolly D, Stern D, Kao J (1993) Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 81:2767-2773
60. Wang L, Yi T, Zhang W, Pardoll DM, Yu H (2010) IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res 70(24):10112-10120. doi:10.1158/0008-5472.CAN-10-0775
61. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Res-tifo NP, Overwijk WW, Dong C (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31(5):787-798. doi:S1074-7613(09)00451-8 [pii]10.1016/j.immuni.2009.09.014
62. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112(2):362-373. doi:10.1182/blood-2007-11-120998
63. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198(4):569-580
64. Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P (2007) CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109(12):5346-5354. doi:blood-2006-10-051318 [pii]10.1182/blood-2006-10-051318
65. Garcia-Hernandez Mde L, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW (2010) Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 184(8):4215-4227. doi:jimmunol.0902995 [pii]10.4049/jimmunol.0902995
66. Gnerlich JL, Mitchem JB, Weir JS, Sankpal NV, Kashiwagi H, Belt BA, Porembka MR, Herndon JM, Eberlein TJ, Goedegebuure P, Linehan DC (2010) Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 185(7):4063-4071. doi:jimmunol.0902609 [pii]10.4049/jimmunol.0902609
67. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA (2010) Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207(3):651-667. doi:jem.20091921 [pii]10.1084/jem.20091921
68. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178(11):6730-6733. doi:178/11/6730 [pii]
69. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, Monticelli S, Lanzavecchia A, Sallusto F (2012) Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 484 (7395) :514-518. doi:10.1038/nature10957
70. Lanca T, Silva-Santos B (2012) The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology 1(5):717-725. doi:10.4161/onci.200682012ONCOIMM0079R [pii]
71. Jochems C, Schlom J (2011) Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236(5): 567-579. doi:ebm.2011.011007 [pii]10.1258/ebm.2011.011007
72. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6(4):824-833. doi:10.1097/JTO.0b013e3182037b76
73. Fialova A, Partlova S, Sojka L, Hromadkova H, Brtnicky T, Fucikova J, Kocian P, Rob L, Bartunkova J, Spisek R (2013) Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer. doi:10.1002/ijc.27759
74. Winkler I, Gogacz M, Rechberger T (2012) Do Th17 cells play an important role in the pathogenesis and prognosis of ovarian cancer?. Ginekol Pol 83(4):295-300
75. Munn DH (2009) Th17 cells in ovarian cancer. Blood 114(6):1134-1135. doi:114/6/1134 [pii]10.1182/blood-2009-06-224246
76. Kim JS, Sklarz T, Banks LB, Gohil M, Waickman AT, Skuli N, Krock BL, Luo CT, Hu W, Pollizzi KN, Li MO, Rathmell JC, Birnbaum MJ, Powell JD, Jordan MS, Koretzky GA (2013) Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol 14(6):611-618. doi:10.1038/ni.2607
77. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883-899. doi:S0092-8674(10)00060-7 [pii]10.1016/j.cell.2010.01.025
78. Naugler WE, Karin M (2008) The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14(3):109-119. doi:S1471-4914(08)00028-2 [pii]10.1016/j.molmed.2007.12.007
79. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117(5):1175-1183. doi:10.1172/JCI31537
80. Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124(4):823-835. doi:S0092-8674(06)00191-7 [pii]10.1016/j.cell.2006.02.016
81. Du JW, Xu KY, Fang LY, Qi XL (2012) Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer. Mol Med Report 6(5):1099-1102. doi:10.3892/mmr.2012.1036
82. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101(7):2620-2627. doi:10.1182/blood-2002-05-14612002-05-1461 [pii]
83. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA (2011) Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10(11):2157-2167. doi:1535-7163.MCT-11-0312 [pii]10.1158/1535-7163.MCT-11-0312
84. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963-969
85. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206(7):1457-1464. doi:jem.20090207 [pii]10.1084/jem.20090207
86. Zhang YL, Li J, Mo HY, Qiu F, Zheng LM, Qian CN, Zeng YX (2010) Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 9:4. doi:1476-4598-9-4 [pii]10.1186/1476-4598-9-4
87. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, Tak PP, Gomez-Reino JJ, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD, Rose K, Haider A, Di Padova F (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2(52):52ra72. doi:2/52/52ra72 [pii]10.1126/scitranslmed.3001107
88. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, Fang W, Xiong B, Wan Y, Dong C (2012) A protective role by interleukin-17F in colon tumorigenesis. PLoS One 7(4):e34959. doi:10.1371/journal.pone.0034959PONE-D-11-11768 [pii]
89. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, Weighardt H, Essler M (2006) IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 177(11):8266-8272. doi:177/11/8266 [pii]
90. Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, Shrikant PA, Griffioen AW (2008) Angiostatic activity of the antitumor cytokine interleukin-21. Blood 112(13):4940-4947. doi:blood-2007-09-113878 [pii]10.1182/blood-2007-09-113878
91. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24(6):677-688. doi:S1074-7613(06)00269-X [pii]10.1016/j.immuni.2006.06.002
92. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rebe C, Ghiringhelli F (2012) Stat3 and Gfi-1 transcription factors control Th17 cell immunosup-pressive activity via the regulation of ectonucleotidase expression. Immunity 36(3):362-373. doi:S1074-7613(12)00082-9 [pii]10.1016/j.immuni.2011.12.019
93. Valmori D, Raffin C, Raimbaud I, Ayyoub M (2010) Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci U S A 107(45):19402-19407. doi:1008247107 [pii]10.1073/pnas.1008247107
94. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112(6):2340-2352. doi:blood-2008-01-133967 [pii]10.1182/blood-2008-01-133967
95. Du J, Huang C, Zhou B, Ziegler SF (2008) Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol 180(7):4785-4792. doi:180/7/4785 [pii]
96. Tartar DM, VanMorlan AM, Wan X, Guloglu FB, Jain R, Haymaker CL, Ellis JS, Hoe-man CM, Cascio JA, Dhakal M, Oukka M, Zaghouani H (2010) FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes. J Immunol 184(7):3377-3385. doi:jimmunol.0903324 [pii]10.4049/jimmunol.0903324
97. Ye J, Su X, Hsueh EC, Zhang Y, Koenig JM, Hoft DF, Peng G (2011) Human tumor-infiltrating Th17 cells have the capacity to differentiate into IFN-gamma+ and FOXP3+ T cells with potent suppressive function. Eur J Immunol 41(4):936-951. doi:10.1002/eji.201040682
98. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, Liu R, Balcarcel RR, Fisher N, Levine BL, Carroll RG, Warner N, Blazar BR, June CH, Riley JL (2008) CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 181(4):2855-2868. doi:181/4/2855 [pii]
99. Kurschus FC, Croxford AL, Heinen AP, Wortge S, Ielo D, Waisman A (2010) Genetic proof for the transient nature of the Th17 phenotype. Eur J Immunol 40(12):3336-3346. doi:10.1002/eji.201040755
100. Annunziato F, Romagnani S (2010) The transient natureofthe Th17 phenotype. EurJ Immunol 40(12):3312-3316. doi:10.1002/eji.201041145
101. Shi G, Lovaas JD, Tan C, Vistica BP, Wawrousek EF, Aziz MK, Rigden RC, Caspi RR, Gery I (2012) Cell-cell interaction with APC, not IL-23, is required for naive CD4 cells to acquire pathogenicity during Th17 lineage commitment. J Immunol 189(3):1220-1227. doi:10.4049/jimmunol.1103033
102. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ (2007) TGF-beta and IL-6 drive the production ofIL-17 and IL-10byT cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390-1397. doi:ni1539 [pii]10.1038/ni1539
103. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O'Shea JJ (2010) Generation of pathogenicT(H)17 cells in the absence of TGF-beta signalling. Nature 467 (7318) :967-971. doi:nature09447 [pii]10.1038/nature09447
104. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ, Roychoudhuri R, Ferreyra GA, Shen W, Durum SK, Feigenbaum L, Palmer DC, Antony PA, Chan CC, Laurence A, Danner RL, Gattinoni L, Restifo NP (2011) Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 35(6):972-985. doi:10.1016/j.immuni.2011.09.019
105. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907-912. doi:10.1084/jem.20050732
106. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP (2007) Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117(8):2197-2204. doi:10.1172/JCI32205
107. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13(18 Pt 1):5280-5289. doi:10.1158/1078-0432.CCR-07-1378
108. Muranski P, Restifo NP (2013) Essentials of Th17 cell commitment and plasticity. Blood 121(13):2402-2414. doi:10.1182/blood-2012-09-378653
109. Lee YK, Mukasa R, Hatton RD, Weaver CT (2009) Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21(3):274-280. doi:S0952-7915(09)00103-4 [pii]10.1016/j.coi.2009.05.021
110. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT (2009) Late developmental plasticity in the T helper 17 lineage. Immunity 30(1):92-107. doi:S1074-7613(08)00546-3 [pii]10.1016/j.immuni.2008.11.005
111. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C (2009) Th17 cells promotepancre-atic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 39(1):216-224. doi:10.1002/eji.200838475
112. Nurieva R, Yang XO, Chung Y, Dong C (2009) Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J Immunol 182(5):2565-2568. doi:182/5/2565 [pii]10.4049/jimmunol.0803931
113. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725-733. doi:10.1056/NEJMoa1103849
114. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269-281. doi:10.1038/nri3191
115. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29(7):917-924. doi:10.1200/JCO.2010.32.2537
116. Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ Jr, Levine BL, Carroll RG, Riley JL, June CH (2008) Adoptive immunother-apy: good habits instilled at youth have long-term benefits. Immunol Res 42(1-3):182-196. doi:10.1007/s12026-008-8070-9
117. Kaech SM, Wherry EJ, Ahmed R (2002) Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2(4):251-262. doi:10.1038/nri778
118. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP (2004) IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101(7):1969-1974. doi:10.1073/pnas.03072981010307298101 [pii]
119. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102(27):9571-9576. doi:0503726102 [pii]10.1073/pnas.0503726102
120. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17(10): 1290-1297. doi:10.1038/nm.2446
121. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15(7):808-813. doi:10.1038/nm.1982
122. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP (2011) Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117(3):808-814. doi:blood-2010-05-286286 [pii]10.1182/blood-2010-05-286286
123. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115(6):1616-1626. doi:10.1172/JCI24480
124. Luckey CJ, Weaver CT (2012) Stem-cell-like qualities of immune memory; CD4+ T cells join the party. Cell Stem Cell 10(2):107-108. doi:10.1016/j.stem.2012.01.011
125. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP (2009) Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med 15(7):808-813
126. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W (2011) Human TH17 cells are long-lived effector memory cells. Sci Transl Med 3(104):104ra100. doi:10.1126/scitranslmed.3002949
127. Yu Y, Iclozan C, Yamazaki T, Yang X, Anasetti C, Dong C, Yu XZ (2009) Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. Blood 114(5):1026-1028. doi:blood-2009-03-210153 [pii]10.1182/blood-2009-03-210153
128. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W (2011) Human TH17 cells are long-lived effector memory cells. Sci Transl Med 3(104):104ra100. doi:10.1126/scitranslmed.3002949
129. Bui JD, Schreiber RD (2007) Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19(2):203-208. doi:S0952-7915(07)00009-X [pii]10.1016/j.coi.2007.02.001
130. Pepper M, Linehan JL, Pagan AJ, Zell T, Dileepan T, Cleary PP, Jenkins MK (2010) Different routes of bacterial infection induce long-lived TH1 memory cells and short-lived TH17 cells. Nat Immunol 11(1):83-89. doi:ni.1826 [pii]10.1038/ni.1826
131. Purvis HA, Stoop JN, Mann J, Woods S, Kozijn AE, Hambleton S, Robinson JH, Isaacs JD, Anderson AE, Hilkens CM (2010) Low-strength T-cell activation promotes Th17 responses. Blood 116(23):4829-4837. doi:blood-2010-03-272153 [pii]10.1182/blood-2010-03-272153
132. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL (2008) Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med 14(12):1390-1395. doi:nm.1779 [pii]10.1038/nm.1779
133. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kam-mula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346-2357. doi:10.1200/JCO.2005.00.240
134. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202(7):907-912
135. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, Restifo NP (2006) Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat Clin Pract Oncol 3(12):668-681. doi:ncponc0666 [pii]10.1038/ncponc0666
136. Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP (2010) Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother 33(1):1-7
137. Driessens G, Zheng Y, Gajewski TF (2010) Beta-catenin does not regulate memory T cell phenotype. Nat Med 16(5):513-514; author reply 514-515. doi:nm0510-513 [pii]10.1038/nm0510-513
138. Driessens G, Zheng Y, Locke F, Cannon JL, Gounari F, Gajewski TF (2011) Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-gamma1 phosphorylation. J Immunol 186(2):784-790. doi:jimmunol.1001562 [pii]10.4049/jimmunol.1001562
139. Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111(11):5326-5333. doi:blood-2007-09-113050 [pii]10.1182/blood-2007-09-113050
140. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, Pearce EJ, Pearce EL (2012) Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36(1):68-78. doi:10.1016/j.immuni.2011.12.007
141. Barbi J, Pardoll D, Pan F (2013) Metabolic control of the Treg/Th17 axis. Immunol Rev 252(1):52-77. doi:10.1111/imr.12029
142. Perry JM, He XC, Sugimura R, Grindley JC, Haug JS, Ding S, Li L (2011) Cooperation between both Wnt/{beta}-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion. Genes Dev 25(18):1928-1942. doi:10.1101/gad.17421911
143. Luckey CJ, Bhattacharya D, Goldrath AW, Weissman IL, Benoist C, Mathis D (2006) Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A 103(9):3304-3309. doi:0511137103 [pii]10.1073/pnas.0511137103
144. Ersvaer E, Melve GK, Bruserud O (2011) Future perspectives: should Th17 cells beconsidered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation? Cancer Immunol Immunother 60(12):1669-1681. doi:10.1007/s00262-011-1118-z
145. Bruserud O (1999) Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. Leukemia 13(8):1175-1187
146. Liu FL, Chen CH, Chu SJ, Chen JH, Lai JH, Sytwu HK, Chang DM (2007) Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway. Rheumatology (Oxford) 46(8):1266-1273. doi:10.1093/rheumatology/kem055
147. Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, Qian J, Jin J, Xu H (2009) Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol 158(2):199-204. doi:10.1111/j.1365-2249.2009.04011.x
148. Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O (2010) Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 11:38. doi:10.1186/1471-2172-11-38
149. Idler I, Giannopoulos K, Zenz T, Bhattacharya N, Nothing M, Dohner H, Stilgenbauer S, Mertens D (2010) Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 148(6):948-950. doi:10.1111/j.1365-2141.2009.08014.x
150. Appelbaum FR (2001) Haematopoietic cell transplantation as immunotherapy. Nature 411 (6835) :385-389
151. Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR (1998) Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 102(9):1742-1748
152. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, Johnston H, Young J, Todorov I, Umetsu DT, Chen L, Iwakura Y, Kandeel F, Forman S, Zeng D (2009) Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 114(14):3101-3112. doi:10.1182/blood-2009-05-219402
153. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, Holland AM, Grubin J, Mark NM, Liu C, Iwakura Y, Heller G, van den Brink MR (2009) IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 113(4):945-952
154. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, LeBon T, Kandeel F, Forman S, Zeng D (2008) Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112(5):2101-2110
155. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS (2009) In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113(6):1365-1374. doi:10.1182/blood-2008-06-162420
156. Iclozan C, Yu Y, Liu C, Liang Y, Yi T, Anasetti C, Yu XZ (2010) T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant 16(2):170-178. doi:S1083-8791(09)00446-7 [pii]10.1016/j.bbmt.2009.09.023
157. Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, Yu XZ (2011) Prevention of GVHD while sparing GVL by targeting Th1 and Th17 transcription factor T-bet and ROR{gamma}t in mice. Blood 118(18):10. doi:10.1182/blood-2011-03-340315
158. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114(3):596-599. doi:10.1182/blood-2009-02-203935
159. Yen HR, Harris TJ, Wada S, Grosso JF, Getnet D, Goldberg MV, Liang KL, Bruno TC, Pyle KJ, Chan SL, Anders RA, Trimble CL, Adler AJ, Lin TY, Pardoll DM, Huang CT, Drake CG (2009) Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol 183(11):7161-7168. doi:jimmunol.0900368 [pii]10.4049/jimmunol.0900368
160. Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ (2013) Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms. J Immunol 190(4):1873-1881. doi:10.4049/jimmunol.1201989
161. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6): 1466-1476. doi:10.1172/JCI32446
162. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP (2006) Adoptive immunotherapy for cancer: building on success. Nat Rev Immunology 6(5):383-393. doi:10.1038/nri1842
163. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gn-jatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358(25):2698-2703. doi:358/25/2698 [pii]10.1056/NEJMoa0800251
164. Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL (2008) Genetic engineering of T cells for adoptive immunotherapy. Immunol Res 42(1-3):166-181. doi:10.1007/s12026-008-8057-6
165. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH (2010) Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 70(22):9053-9061. doi:10.1158/0008-5472.CAN-10-2880
166. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O, Wang N, Lee G, Bartsevich VV, Lee YL, Guschin DY, Rupniewski I, Waite AJ, Carpenito C, Carroll RG, Orange JS, Urnov FD, Rebar EJ, Ando D, Gregory PD, Riley JL, Holmes MC, June CH (2008) Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26(7):808-816. doi:10.1038/nbt1410
167. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73. doi:10.1126/scitranslmed.3002842
168. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK (2012) Monoclonal TCR-redirected tumor cell killing. Nat Med. doi:10.1038/nm.2764
169. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453-1464. doi:10.1038/mt.2009.83
170. Chmielewski M, Hombach A, Heuser C, Adams GP, Abken H (2004) T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol 173(12):7647-7653. doi:173/12/7647 [pii]
171. Al-Khami AA, Mehrotra S, Nishimura MI (2011) Adoptive immunotherapy of cancer: Gene transfer of T cell specificity. Self Nonself 2(2):80-84. doi:10.4161/self.2.2.158321938-2030-2-2-2 [pii]
172. Garaude J, Blander JM (2010) ICOStomizing immunotherapies with T(H)17. Sci Transl Med 2(55):55ps52. doi:2/55/55ps52 [pii]10.1126/scitranslmed.3001722
173. Yu XZ, Liang Y, Nurieva RI, Guo F, Anasetti C, Dong C (2006) Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells. J Immunol 176(12):7394-7401. doi:176/12/7394 [pii]
174. Crompton JG, Rao M, Restifo NP (2013) Memoirs of a reincarnated T cell. Cell Stem Cell 12(1):6-8. doi:10.1016/j.stem.2012.12.009
175. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12(1):114-126. doi:10.1016/j.stem.2012.11.002
176. Vizcardo R, Masuda K, Yamada D, Ikawa T, Shimizu K, Fujii S, Koseki H, Kawamoto H (2013) Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells. Cell Stem Cell 12(1):31-36. doi:10.1016/j.stem.2012.12.006